The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

In March 2022,[177Lu] Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the
treatment of prostate cancer patients. Until now, the approval has been limited to patients …

Metastasis remains a pivotal characteristic of cancer and is the primary contributor to cancer-
associated mortality. Despite its significance, the mechanisms governing metastasis are not …

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …

Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …

Molecular imaging has experienced enormous advancements in the areas of imaging
technology, imaging probe and contrast development, and data quality, as well as machine …